Many researchers have explored the therapeutic potential of other immune checkpoints; TIM-3, LAG-3, and T cell immunoglobulin and ITIM domains (TIGIT) are under exploration, with promising results obtained in mediating anti-tumor immunity [5, 6, 77]. The gene discussed is HAVCR2; the disease is neoplasm.